- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00610922
Docosaexahenoic Acid and Gross Motor Milestones in Infants
February 7, 2008 updated by: University of Milan
RCT of Supplemented Docosahexaenoic Acid and Gross Motor Development Milestones in Healthy Infants.
To examine whether daily supplement of docosahexaenoic acid throughout the first year of life may speed up the achievement of gross motor development milestones in healthy infants, a total of 1160 healthy infants randomly allocated to receive throughout the first year of life daily oral supplement of vitamin D3 (400 IU) plus docosahexaenoic acid (20 mg) or vitamin D3 (400 IU) alone.
Primary outcome measure: time of achieving gross motor development milestones.
Secondary outcome measure: time of achieving early fine motor development milestones and language.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1160
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 day to 1 week (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- weight at birth equal or above 2500 g;
- gestational age between 37 and 42 completed weeks;
- single birth;
- absence of neonatal or birth abnormalities;
- Apgar score greater than or equal to 7 at 5 m;
- white parents.
Exclusion Criteria:
- presence of neonatal diseases requiring hospitalisation for longer than 7 days;
- unknown father;
- parents unable to understand the protocol requirements and to fill out the infants diary;
- infant already enrolled or selected for another clinical study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 2
|
DHA 20 mg per day through 12 months of life
|
|
No Intervention: 1
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
time of achieving the four gross motor development milestones
Time Frame: 4, 8 and 12 months of age
|
4, 8 and 12 months of age
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
time of achieving early fine motor milestones and language
Time Frame: 4, 8 and 12 months of age
|
4, 8 and 12 months of age
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Carlo Agostoni, Prof, Dept. of Pediatrics, San Paolo Hospital, University of MIlan, Italy
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Primary Completion (Actual)
December 1, 2006
Study Completion (Actual)
December 1, 2006
Study Registration Dates
First Submitted
January 28, 2008
First Submitted That Met QC Criteria
February 7, 2008
First Posted (Estimate)
February 8, 2008
Study Record Updates
Last Update Posted (Estimate)
February 8, 2008
Last Update Submitted That Met QC Criteria
February 7, 2008
Last Verified
January 1, 2008
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- NEON-02/2005-DHA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.